NCT00335751

PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma

Glucose Metabolic Response by PET/CT to Sarcoma Treatments

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Jonsson Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Diagnostic procedures, such as PET scan and CT scan, may help doctors determine the extent of cancer and predict a patient's response to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying how well PET scan combined with CT scan evaluates treatment response in patients undergoing treatment for bone cancer or soft tissue sarcoma.

Detailed description

OBJECTIVES: * Determine whether an FDA-approved device that combines fludeoxyglucose \^18F positron-emission tomography (FDG-PET) and CT scanning (FDG-PET/CT) can accurately locate and determine the extent of disease in patients who are undergoing treatment for bone or soft tissue sarcoma. * Determine whether FDG-PET/CT scanning is effective in evaluating the response of sarcoma to treatment. * Determine whether the new FDG-PET/CT device improves the ability to evaluate treatment response early and accurately. * Correlate changes in glucose metabolic activity early and late after treatment with overall and progression-free survival. * Correlate changes in glucose metabolic activity early and late after treatment with degree of tumor necrosis at the time of surgery. OUTLINE: This is a prospective, pilot study. Patients are stratified according to disease (high-grade soft tissue sarcoma vs low-grade soft tissue sarcoma vs osteosarcoma). Patients undergo fludeoxyglucose \^18F positron-emission tomography (FDG-PET)/CT scanning at baseline and then within 2 weeks and 12 weeks after the start of treatment (total of 3 scans). PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.

Conditions

• Sarcoma

Interventions

Type	Name	Description
PROCEDURE	positron emission tomography computed tomography (PET/CT)	The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.

Timeline

• Start date: 2006-01-01
• Primary completion: 2008-07-01
• Completion: 2011-10-01
• First posted: 2006-06-12
• Last updated: 2020-07-31

Locations

1 site across 1 country: United States